Big Pharma gets paid by governments for vaccines whether vials get used or not

Even though Canada ultimately ended up not needing nearly as many Wuhan coronavirus (COVID-19) “vaccines” as it originally thought, Canadian taxpayers are still being forced to pay $350 million to Novavax Inc. for a number of jabs that were never even delivered, let alone distributed.

According to reports, Novavax, which is based out of the United States but was not included in this country’s COVID jab rollout, also reached a deal with Canada’s public works and government services department to amend the advance purchase contract after it became clear that far fewer people were lining up for COVID jabs than what was anticipated.

Novavax produced way more injection vials than were needed, in other words. But rather than eat the cost like companies in other industries do, the pharmaceutical giant is demanding compensation for products undelivered that were never used.

The company announced that the number of jab doses due for delivery has now been reduced, while the schedule for remaining doses to be shipped has since been revised under the amended terms.

(Related: Earlier this year, a conservative member of the British parliament was called “antisemitic” for criticizing COVID injections.)

Without this massive cash infusion from Canadian taxpayers, Novavax faces imminent bankruptcy and collapse

We are told that Novavax will receive that $350 million payout in two equal installments in 2023, even though the original value of the contract remains unchanged.

The Canadian government can still terminate its contract with the company if it fails to achieve regulatory approval for jab production at the Biologics Manufacturing Centre by Dec. 31, 2024.

“Novovax – which has its COVID-19 vaccine as the only marketed product after 35 years in business – has raised doubts about its ability to remain in business, flagging uncertainties around its revenue and funding crunch,” Reuters reported about the matter.

“The company said in May it expects 2023 revenue between $1.4 billion and $1.6 billion, of which $800 million was from ‘locked-in’ overseas purchase contracts for the COVID shot that it has committed to ship this year.”

In other words, were Canadian taxpayers not being forced to subsidize Novavax’s oversized non-delivery of unneeded COVID jabs, the company faces imminent bankruptcy and collapse.

In fact, the company revealed that it might not even survive through the end of 2023 if the cash infusion is not made.

Canada approved both a primary series of Novavax’s recombinant protein jab Nuvaxovid as well as a booster through a deal signed in 2021. Plans are in the works, as aforementioned, to produce the injection locally in Canada at the National Research Council of Canada’s Biologics Manufacturing Centre (BMC) in Montreal.

In an effort to expand its commitment to the Canadian market, Novavax says it will “provide health, economic, and future pandemic preparedness benefits to Canada,” including through the potential signing of a 15-year memorandum of understanding worth at least the remaining amount of what Canada plans to pay Novavax for its existing COVID jab orders.

According to reports, nobody wants to get injected for COVID anymore, which means there are a lot of leftover injections with nowhere to go but the dustbin. This is also true for the COVID jabs from AstraZeneca, with roughly 13.6 million doses of its shots in Canada scheduled to go to landfills.

Another lesser-known “plant-based” COVID injection called Covifenz is also doing poorly, driving its manufacturer, Canada-based Medicago, into bankruptcy this year. It turns out that Medicago could never find a market for its COVID shot, especially after it became clear the “pandemic” was pretty much a hoax.

The latest news about the fallout from Operation Warp Speed and other COVID jab measures in the U.S., Canada and elsewhere can be found at Genocide.news.

Sources for this article include:

Reuters.com

Newstarget.com

FiercePharma.com